Sanguinarine	O
induces	O
apoptosis	O
of	O
human	O
osteosarcoma	B-Cell
cells	I-Cell
through	O
the	O
extrinsic	O
and	O
intrinsic	O
pathways	O
.	O

The	O
quaternary	O
benzo	O
[	O
c	O
]	O
phenanthridine	O
alkaloid	O
sanguinarine	O
inhibits	O
the	O
proliferation	O
of	O
cancerous	B-Cell
cells	I-Cell
from	O
different	O
origins	O
,	O
including	O
lung	B-Organ
,	O
breast	B-Organism_subdivision
,	O
pancreatic	B-Organ
and	O
colon	B-Organ
,	O
but	O
nothing	O
is	O
known	O
of	O
its	O
effects	O
on	O
osteosarcoma	B-Cancer
,	O
a	O
primary	B-Cancer
malignant	I-Cancer
bone	I-Cancer
tumour	I-Cancer
.	O

We	O
have	O
found	O
that	O
sanguinarine	O
alters	O
the	O
morphology	O
and	O
reduces	O
the	O
viability	O
of	O
MG	B-Cell
-	I-Cell
63	I-Cell
and	O
SaOS	B-Cell
-	I-Cell
2	I-Cell
human	I-Cell
osteosarcoma	I-Cell
cell	I-Cell
lines	I-Cell
in	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Incubation	O
with	O
1	O
micromol	O
/	O
L	O
sanguinarine	O
for	O
4	O
and	O
24h	O
killed	O
more	O
efficiently	O
MG	B-Cell
-	I-Cell
63	I-Cell
cells	I-Cell
than	O
SaOS	B-Cell
-	I-Cell
2	I-Cell
cells	I-Cell
,	O
while	O
incubation	O
with	O
5	O
micromol	O
/	O
L	O
sanguinarine	O
killed	O
almost	O
100	O
%	O
of	O
both	O
cell	B-Cell
populations	I-Cell
within	O
24h	O
.	O

This	O
treatment	O
also	O
changed	O
the	O
mitochondrial	B-Cellular_component
membrane	I-Cellular_component
potential	O
in	O
both	O
MG	B-Cell
-	I-Cell
63	I-Cell
and	O
SaOS	B-Cell
-	I-Cell
2	I-Cell
cells	I-Cell
within	O
1h	O
,	O
caused	O
chromatin	B-Cellular_component
condensation	O
and	O
the	O
formation	O
of	O
apoptotic	B-Cellular_component
bodies	I-Cellular_component
.	O

It	O
activated	O
multicaspases	O
,	O
and	O
increased	O
the	O
activities	O
of	O
caspase	O
-	O
8	O
and	O
caspase	O
-	O
9	O
in	O
both	O
MG	B-Cell
-	I-Cell
63	I-Cell
and	O
SaOS	B-Cell
-	I-Cell
2	I-Cell
cells	I-Cell
.	O

These	O
data	O
highlight	O
sanguinarine	O
as	O
a	O
novel	O
potential	O
agent	O
for	O
bone	B-Cancer
cancer	I-Cancer
therapy	O
.	O

